Lv41
770 积分 2025-11-16 加入
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case–control study of abemaciclib-induced interstitial lung disease (NOSIDE)
1个月前
已完结
Early toxicity–driven dose modification and efficacy of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: A real-world study in Chinese patients
1个月前
已完结
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
1个月前
已完结
44O Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE
1个月前
已完结
肿瘤内科发热性中性粒细胞减少患者药物治疗临床路径的应用探索
2个月前
已完结
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial
3个月前
已完结
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
3个月前
已完结
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
3个月前
已完结
Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study
5个月前
已完结
Toxicity profiles of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors: safety analysis from clinical trials and the FDA Adverse Event Reporting System (FAERS)
7个月前
已完结
皖公网安备34019202002308
